Navigation Links
NanoLogix Inc. Appoints Two New Directors and Provides Operations Update

HUBBARD, Ohio, Jan. 12 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (OTC: NNLX) a biotechnology company, announces director appointments and provides operations update.

NanoLogix welcomes Daniel Barnhizer and Jeff Long to the Board of Directors. Daniel Barnhizer is an associate professor of law at Michigan State University College of Law, where he teaches and writes in the areas of business, contract, securities, and commercial law. In addition to his academic work, Professor Barnhizer also maintains an active consulting practice in corporate and securities law. Prior to joining the MSU College of Law faculty in 2001, Professor Barnhizer worked as a litigator in Washington, D.C. with the law firms of Hogan & Hartson and Cadwalader, Wickersham & Taft, where his primary practice areas focused on corporate governance, securities law, and white collar criminal law. Professor Barnhizer graduated with honors from Harvard Law School in 1995 where he was Managing Editor of the Harvard Environmental Law Review.

Jeff Long is a novelist, historian, advertising writer, and human rights advocate, He has authored eight novels, one of which was a New York Times bestseller, and two non-fiction works. He has written and developed advertising and catalogs for various companies including Overseas Adventure Travel, Lowe Alpine Systems, Thompson Safaris, and others, and is the founder of Witness Inc., a human rights and foreign aid group. Additional details about Jeff are available on

NanoLogix has secured additional square footage for the production of their BNPTM Rapid Detection kits and is awaiting financing prior to the build-out of the planned production clean-rooms and shipping/receiving area. The additional area is adjacent to the existing NanoLogix headquarters and more than doubles current company space in Hubbard, Ohio to approximately 4,000 square feet. The company also announces its intention to hold a 2009 shareholder meeting during the second quarter, with the date to be announced.

CEO Bret Barnhizer stated, "The addition of Daniel Barnhizer and Jeff Long to our Board of Directors brings two very capable people to the Company --- Daniel, for his expertise in multiple aspects of corporate and business law; and Jeff Long, for both his advertising experience, business acumen, and an outstanding ability to develop new paradigms. We look forward to their contributions to the company." Director John Chatterton remarked: "I look forward to working with our new Board Members and having Nanologix capitalize on both their creativity and expertise."

Regarding the addition of space for production of BNPTM kits, Bret Barnhizer said "All of us in NanoLogix are elated at the prospects for ramping up production beyond the five-hundred per week capability of our Cincinnati facility. The Hubbard expansion should provide the capability to produce 48,000 kits per week".

About NanoLogix, Inc.

NanoLogix is an industry innovator in the research, development, and commercialization of biotechnologies, applications and processes. The Company has multiple Patents and Patents Pending for rapid medical testing, bioremediation, and Hydrogen Production utilizing bioreactor technology. Information on NanoLogix is available at

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

    Investor Relations
    Carol Surrena
    Telephone: 330-534-0800

SOURCE NanoLogix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NanoLogix Inc. Announces Joint Development With CL Solutions and First Sales of Rapid Detection Kits
2. NanoLogix Inc. to Present at The American Society for Microbiology (ASM) General Meeting in Boston; Announces Product Line and Provides Operations Update
3. NanoLogix Inc. Provides Financial Update, Appoints Bert Pharis as New Director
4. NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update
5. National Public Radio (NPR) Features Broadcast Articles on NanoLogix Hydrogen Bioreactor Operation at Welchs Foods
6. NanoLogixs Hydrogen-From-Waste Technology at Welchs Foods Featured on Environmental Radio Program
7. NanoLogix, Inc. Makes Stock Pick List
8. NanoLogix Inc. Sets Date for Annual Shareholder Meeting and Provides Shareholder Update
9. NanoLogix Inc. to Present at EBW Expo & Conference 2007
10. NanoLogix Inc. Announces Historical First in Energy Generation With Bioreactor-Produced Hydrogen at Welchs
11. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is pleased ... technical presentations offered in symposia, oral sessions, workshops, awards, and posters. The ... range of applications such as, but not limited to, biotechnology, biomedical, drug discovery, ...
(Date:11/26/2015)... 26, 2015 ... Accutest Research Laboratories, a leading independent ... (CRO), has formed a strategic partnership ... Temple Health for joint work on ... ) , --> ...
(Date:11/25/2015)... , November 26, 2015 ... Biobanking Market 2016 - 2020 report analyzes that ... integrity and quality in long-term samples, minimizing manual ... cost-effectiveness. Automation minimizes manual errors such as mislabeling ... efficiency. Further, it plays a vital role in ...
(Date:11/25/2015)... 25, 2015 2 nouvelles études permettent ... les différences entre les souches bactériennes retrouvées dans la ... des êtres humains . Ces recherches  ouvrent une nouvelle ... prise en charge efficace de l,un des problèmes ... chats .    --> 2 nouvelles études ...
Breaking Biology Technology:
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
(Date:10/27/2015)... In the present market scenario, security is ... industry verticals such as banking, healthcare, defense, electronic gadgets, ... for secure & simplified access control and growing rate ... of bank accounts, misuse of users, , and so ... laptops, and smartphones are expected to provide potential opportunities ...
Breaking Biology News(10 mins):